- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03988790
Evaluation of the Response to Monoclonal Antibody Therapy in Severe Asthma: Research of Predictive Biomarkers in Exhaled Air (Zina-VOC)
Evaluation of Response to Monoclonal Antibody Therapy in Severe Asthma: Research of Predictive Biomarkers in Exhaled Air
Study Overview
Detailed Description
At least one in two patients treated by monoclonal antibody for severe asthma doesn't have satisfying result after 6 months of treatment.
The evaluation of the answer, and even better the answer prediction, are fundamental issues for medico-economic plan as part of these innovative therapeutics.
The interest of the use of VOC as diagnostic or prognostic tool in patients with tumoral thoracic pathology or bronchial or pulmonary vascular diseases has been demonstrated.
VOC analysis will be performed using two different techniques: electronic nose and masse spectrometry. At each visit, in addition to the usual assessment, patients will have two non-invasives collections of exhaled air, one for electronic nose analysis and one for masse spectrometry analysis.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Suresnes, France, 92150
- Recruiting
- Hopital FOCH
-
Contact:
- Philippe Devillier
- Phone Number: + 33 1 46 25 27 91
- Email: p.devillier@hopital-foch.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- patient aged > 18 years old
- patient with severe asthma who respond to the indication of monoclonal antibody therapy according to SPC and management criteria fixed by Transparency Committee
- signed informed consent
- patient with healthcare insurance
Exclusion Criteria:
- patient not responding to the criteria for the good use of monoclonal antibody in severe asthma
- contraindication to one of monoclonal antibody treatment according to SPC (hypersensitivity to one of compounds)
- patient unable to perform a slow vital capacity
- patient with long-term oxygen therapy , under invasive ventilation
- pregnant women
- patient deprived of liberty by judicial or administrative decision
Study Plan
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: VOC analysis
VOC analysis in exhaled air in patients with severe asthma treated by monoclonal antibody
|
VOC analysis in exhaled air with e-noses and mass spectrometry.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of Volatil Organic Compound (VOC) profiles predictive of clinically significant response
Time Frame: 1 day
|
Clinically significant response defined by:
|
1 day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of FEV and FEV/CV
Time Frame: change from baseline profiles at 3, 6 and12 months post-baseline
|
Predictive variations of a clinically relevant response with improvement of FEV and FEV/CV at 3, 6 and 12 months
|
change from baseline profiles at 3, 6 and12 months post-baseline
|
Decrease of residual volume
Time Frame: change from baseline profiles at 3, 6 and12 months post-baseline
|
Predictive variations of a clinically relevant response with decrease of residual volume (RV) at 3, 6 and 12 months
|
change from baseline profiles at 3, 6 and12 months post-baseline
|
Decrease of the daily dose of oral corticosteroids
Time Frame: change from baseline profiles at 1, 3, 6 and12 months post-baseline
|
Predictive variations of a clinically relevant response with decrease of the daily dose of oral corticosteroids for corticosteroid-dependent patients at 1, 3, 6 and 12 months
|
change from baseline profiles at 1, 3, 6 and12 months post-baseline
|
Reduction in the number of exacerbations
Time Frame: change from baseline profiles at 1, 3, 6 and12 months post-baseline
|
50% reduction in the number of exacerbations treated with oral steroids after 6 months of treatment compared to the number of exacerbations in the previous year OR a 3 point increase in the ACT (Asthma Control Test) score after 3 months of treatment maintained at 6 months OR increase of GETE (global evaluation of treatment effectiveness) score at 1, 3, 6 and 12 months
|
change from baseline profiles at 1, 3, 6 and12 months post-baseline
|
Change before and after treatment
Time Frame: change from baseline profiles at 12 months post-baseline
|
Change of Volatil Organic Compound (VOC) profiles before and after treatment whatever is the clinical answer
|
change from baseline profiles at 12 months post-baseline
|
Change according to administered antibody
Time Frame: 1 day
|
Change of Volatil Organic Compound (VOC) profiles according to administered antibody
|
1 day
|
Volatil Organic Compound (VOC) profiles according to patients' phenotype
Time Frame: 1 day
|
Volatil Organic Compound (VOC) profiles according to patients' phenotype at the inclusion
|
1 day
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2018_0075
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
SingHealth PolyclinicsNot yet recruitingAsthma | Asthma in Children | Asthma Attack | Asthma Acute | Asthma Chronic
-
Johann Wolfgang Goethe University HospitalCompleted
-
Universita di VeronaCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Value Outcomes Ltd.AstraZenecaCompletedAsthma, Bronchial | Bronchial Asthma | Asthma Chronic | Asthma; EosinophilicCzechia
Clinical Trials on VOC analysis
-
Hopital FochAir Liquide SARecruitingChronic Obstructive Pulmonary Disease ExacerbationFrance
-
Hopital FochUnknownLung Cancer, Non-small CellFrance
-
Hopital FochTerminated
-
Hopital FochAir Liquide SARecruitingChronic Obstructive Pulmonary Disease SevereFrance
-
University of RostockProf. Dr. Daniel A. Reuter, Head of Department, Department of Anesthesiology... and other collaboratorsRecruitingMuscle Weakness | Frailty | Volatile Organic Compounds | IsopreneGermany
-
Fondation Ophtalmologique Adolphe de RothschildNot yet recruiting
-
Medical University of GrazUniversity of Rostock; Graz University of TechnologyUnknown
-
University of LatviaUppsala University; Pontificia Universidad Catolica de Chile; Technion, Israel... and other collaboratorsRecruitingScreening of Gastric Cancer Via Breath Volatile Organic Compounds by Hybrid Sensing Approach (VOGAS)Gastric Cancer | Gastric Dysplasia | Atrophic Gastritis | H.Pylori InfectionBrazil, Chile, Colombia, Latvia, Ukraine
-
University Hospitals Coventry and Warwickshire...University of Leeds; University of Manchester; University of WarwickRecruitingColorectal Cancer | Colorectal Disorders | Colorectal Adenoma | Colorectal PolypUnited Kingdom
-
GCS Ramsay Santé pour l'Enseignement et la RechercheCompletedComplex Post-Traumatic Stress DisorderFrance